A health technology company, Legion Health, is set to launch an artificial intelligence program next month aimed at facilitating the renewal of psychiatric medications. The initiative, beginning in Utah, seeks to provide a more efficient and cost-effective alternative to traditional prescription processes, which often involve extended waiting periods and substantial co-payments.

Legion Health, established in 2021 with $7 million in funding, states its AI system marks the first global authorization for AI to prescribe specific psychiatric medications. The program's scope is currently limited to "lower-risk psychiatric maintenance medications," including SSRIs, Wellbutrin, trazodone, and mirtazapine, provided a human physician has previously prescribed them.

The service will be accessible to patients in Utah for a monthly subscription fee of $20, with plans for expansion into other states. Patients will use an app or web browser, explicitly consenting to interact with an AI agent. Following identity verification, the AI conducts a two-minute safety review, assessing potential drug interactions, side effects, and psychiatric warning signs. Any detected red flags automatically trigger human intervention, and patients retain the option to request a human review at any point.

Arthur MacWaters, a co-founder of Legion Health, described the long-term vision: "The long-term goal is to build the ‘AI doctor’ not as a black box that does everything, but as AI + doctors + clinic in the loop that can handle specific clinical tasks safely, transparently and at scale.” Co-founder Daniel Wilson highlighted the burden on patients, including significant out-of-pocket expenses and travel for renewals. The company emphasizes the critical shortage of health professionals in Utah, where all 29 counties are designated as health professional shortage areas, contributing to difficulties in accessing basic prescription renewals.

Utah has adopted a "middle way" approach to AI regulation, implementing regulatory sandboxes that allow companies to test new technologies by temporarily bypassing certain regulations. Margaret Woolley Bussee, Executive Director of the Utah Department of Commerce, indicated the state's intent to "forge our own path," avoiding extreme positions on AI.

This regulatory stance contrasts with that of other states, such as New York, where proposed legislation could prohibit AI systems like ChatGPT from answering health-related inquiries, even basic ones. This divergence underscores a broader national debate regarding the appropriate role of AI in healthcare, with some viewing it as a solution to access challenges and others expressing concerns about potential risks. MacWaters expressed confidence in AI's future role, stating, "Every patient is going to have AI working on their behalf in five years."